Skip to main content

Table 2 Acquisition rates of CRPA, CRAB, and CRE in clinical specimens between the intervention and control periods

From: Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial

Ā 

Intervention period,

per 1000 person-days (95% CI)

Control period,

per 1000 person-days (95% CI)

Incidence rate ratio (95% CI)

P value

Modified intention-to-treat analysisa

Total

1.75 (0.87–3.13)

3.33 (2.16–4.92)

0.53 (0.23–1.11)

0.07

CRPA

0.32 (0.04–1.15)

1.07 (0.46–2.10)

0.30 (0.03–1.50)

0.10

CRAB

0.80 (0.26–1.86)

1.73 (0.92–2.96)

0.46 (0.13–1.37)

0.13

CRE

0.80 (0.26–1.86)

0.93 (0.38–1.92)

0.85 (0.21–3.12)

0.79

  1. CRPA carbapenem-resistant P. aeruginosa; CRAB carbapenem-resistant A. baumannii; CRE carbapenem-resistant Enterobacterales; CI confidence interval
  2. aExcluding SICU2 in both periods 1 and 2